Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Actinomycin Quadruplex

February 1, 2010 | A version of this story appeared in Volume 88, Issue 5

I was intrigued to learn that actinomycin D is a quadruplex agent inhibiting the c-myc promoter (C&EN, Nov. 2, 2009, page 28). This nicely addresses the findings presented by K. Nishikura and J. M. Murray in their paper "The mechanism of inactivation of the normal c-myc gene locus in human Burkitt lymphoma cells" (Oncogene 1988, 2, 493). As pointed out in your article, c-myc mutations occur in many malignancies, with Burkitt lymphoma being the prototype. Actinomycin D is not in our therapeutic repertoire for Burkitt lymphoma and is worth invesigating in relapsed patients.

Thomas Reid
Conway, Ark.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.